Publication:
Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

Simple item page
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsYumuk, PF; Turhal, NS; Gumus, M; Hatabay, NF; Turken, O; Ozkan, A; Salepci, T; Aliustaoglu, M; Ahiskali, R
dc.date.accessioned2022-03-14T10:02:00Z
dc.date.available2022-03-14T10:02:00Z
dc.date.issued2005-12
dc.description.abstractBackground: Both paclitaxel ( P) and carboplatin ( C) have significant activity in non-small cell lung cancer (NSCLC). The weekly administration of P is active, dose intense, and has a favorable toxicity profile. We retrospectively reviewed the data of 51 consecutive patients receiving C and day 1 and 8 P chemotherapy (CT) regimen in advanced stage NSCLC to evaluate the efficacy and toxicity. Methods: Patients treated in our institutions having pathologically proven NSCLC, no CNS metastases, adequate organ function and performance status (PS) ECOG 0-2 were given P 112.5 mg/m(2) intravenously (IV) over 1 hour on day 1 and 8, followed by C AUC 5 IV over 1 hour, repeated in every three weeks. PC was given for maximum of 6 cycles. Results: Median age was 58 ( age range 39-77) and 41 patients (80%) were male. PS was 0/1/2 in 29/17/5 patients and stage was IIIA/IIIB/IV in 3/14/34 patients respectively. The median number of cycles administered was 3 ( 1 6). Seven patients (14%) did not complete the first 3 cycles either due to death, progression, grade 3 hypersensitivity reactions to P or lost to follow up. Best evaluable response was partial response (PR) in 45% and stable disease (SD) in 18%. Twelve patients (24%) received local RT. Thirteen patients (25%) received 2nd line CT at progression. At a median follow-up of 7 months (range, 1-20), 25 (49%) patients died and 35 patients (69%) progressed. Median overall survival ( OS) was 11 +/- 2 months (95% CI; 6 to 16), 1-year OS ratio was 44%. Median time to progression (TTP) was 6 +/- 1 months (95% CI; 4 to 8), 1-year progression free survival (PFS) ratio was 20%. We observed following grade 3 toxicities: asthenia (10%), neuropathy (4%), anorexia (4%), anemia (4%), hypersensitivity to P (2%), nausea/vomiting (2%), diarrhea ( 2%) and neutropenia (2%). Two patients (4%) died of febrile neutropenia. Doses of CT were reduced or delayed in 12 patients (24%). Conclusions: P on day 1 and 8 and C every three weeks is practical and fairly well tolerated outpatient regimen. This regimen seems to be comparably active to regimens given once in every three weeks.
dc.identifier.doi10.1186/1471-2407-5-10
dc.identifier.issn1471-2407
dc.identifier.pubmed15667664
dc.identifier.urihttps://hdl.handle.net/11424/243926
dc.identifier.wosWOS:000226866200001
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofBMC CANCER
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPHASE-II
dc.subjectRANDOMIZED-TRIAL
dc.subjectCHEMOTHERAPY
dc.subjectCISPLATIN
dc.subjectETOPOSIDE
dc.subjectDURATION
dc.subjectTAXOL
dc.titleResults of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.id5da18c6c-dee5-4e36-a191-d4672051567c
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber10
local.journal.numberofpages7
oaire.citation.titleBMC CANCER
oaire.citation.volume5
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication.latestForDiscovery4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Yumuk et al. - 2005 - Results of paclitaxel (day 1 and 8) and carboplati.pdf
Size:
221.89 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs